Senti Biosciences, Inc.

Developer of programmable and controllable therapeutics via gene circuit platform responsive to disease states

Senti Bio was founded in 2016 to develop scalable programming of synthetic gene circuits as adaptive therapies. Senti’s gene circuit platform programs cells to be targeted and responsive to disease states, which enables advanced therapeutics with unprecedented levels of activity and control. Backed by a syndicate of leading biotech and tech investors including NEA, 8VC, Lux, Pear, Menlo Ventures, and Amgen Ventures, and led by an experienced team with deep translational knowledge of advanced cell therapies, the company is leveraging its proprietary gene circuit repertoire to solve the most pressing unmet needs in oncology and other difficult disease areas.